A Phase 1/2 interventional study of BYL719 and AMG 479 in PIK3CA Mutated Advanced Solid Tumors and PIK3CA Amplified Advanced Solid Tumors, sponsored by Novartis Pharmaceuticals. Terminated at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing alpelisib in Breast Neoplasms — 3 open to participants now, 12 under way, 2 of them phase 3. Alpelisib · Breast Neoplasms.
Among the 38 studies testing alpelisib in Breast Neoplasms, this one is the 16th largest by enrollment, is one of 2 that started in 2012, is one of 4 in phase 1/2, and was the 4th registered.
14,832 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →3 of the 38 studies testing alpelisib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
Novartis Pharmaceuticals
By country, each count listing its studies:
Alpelisib: first FDA approval 2019 (PIQRAY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, alpelisib is the treatment under test here. Read study by study →
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 19 · Phase 3 5
First in 2010; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 44 across the 38 interventional studies. Of the 25 that completed or were terminated, 10 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 112th largest by enrollment of the 155 interventional ones that give a count, is one of 17 that started in 2012, is one of 12 in phase 1/2, and was the 92nd registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
7 of the studies testing alpelisib in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
| NCT05660083The Methodist Hospital Research InstituteAlpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | 2026-12-01 |
| NCT04544189Novartis PharmaceuticalsStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer | 2027-01-29 |
| NCT01872260Novartis PharmaceuticalsStudy of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | 2027-02-26 |
Add all 7 to your calendar (.ics) → With an account.
Among the 38 studies testing alpelisib in Breast Neoplasms, from their registry updates:
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This was a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part was to estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the combination of BYL719 and AMG 479 (ganitumab), followed by the phase II part to assess the clinical efficacy and to further assess the safety of the combination in selected patient populations. Patients were to be treated until progression of disease, unacceptable toxicity develops, or withdrawal of informed consent, whichever occurred first. All patients were to be followed up. At a minimum, patients must have completed the safety follow-up assessments 30 days after the last dose of the study treatment.
This was a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part was to estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the combination of BYL719 and AMG 479 (ganitumab), followed by the phase II part to assess the clinical efficacy and to further assess the safety of the combination in selected patient populations. The dose escalation part of the study were to be guided by a Bayesian Logistic Regression Model (BLRM).
Once MTD/RP2D had been determined, patients were to be enrolled in two Phase II arms. Patients with PIK3CA mutated or amplified hormone receptor positive breast carcinoma were to be enrolled in Arm 1; patients with PIK3CA mutated or amplified ovarian carcinoma were to be enrolled in Arm 2. Patients were to be treated until progression of disease, unacceptable toxicity develops, or withdrawal of informed consent, whichever occurred first. All patients were to be followed up. At a minimum, patients must have completed the safety follow-up assessments 30 days after the last dose of the study treatment.
Key inclusion criteria:
Key exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For: Dose escalation phase/Phase II Expansion Phase. Cohorts of 3-6 patients were to be enrolled sequentially until an MTD or a recommended Phase II dose were defined. All patients were to receive the combination treatment. Sequential cohorts may receive different doses of the combination. In the Phase II expansion, all patients were to receive the same combination treatment.
Drug: BYL719 · Drug: AMG 479
Dose Limiting Toxicities (DLTs) - Phase Ib
Phase lb only
Time frame: 28 days
Percentage of Patients With Overall Response Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II
The antitumor activity of alpelisib in combination with ganitumab in patients with PIK3CA mutated or amplified hormone receptor positive (HR+) breast (arm 1) or ovarian (arm 2) cancer. Overall response rate is defined as the proportion of patients who have a best overall response of complete response or partial response assessed per RECIST 1.1.
Time frame: Approximately 1 year (since initiation of Phase II, Dec 2013, till Primary CSR cut off 06Jan2015)
Number of Patients With Best Overall Response (RECIST) Based on Investigator Radiology Assessment - Phase Ib
The anti-tumor activity of alpelisib and ganitumab in combination as per RECIST 1.1
Time frame: Approximately 1 year (since FPFV 27Nov2012, till MTD declaration 26Nov2013)
Percentage of Patients With Disease Control Rate (RECIST) Based on Investigator Radiology Assessment - Phase Ib
The anti-tumor activity of alpelisib and ganitumab in combination as per RECIST 1.1
Time frame: Approximately 1 year (since FPFV 27Nov2012, till MTD declaration 26Nov2013)
Percentage of Patients With Disease Control Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II
the antitumor activity of alpelisib in combination with ganitumab in patients with PIK3CA mutated or amplified hormone receptor positive (HR+) breast (arm 1) or ovarian (arm 2) cancer. Phase II only, Cycle 1 Day 1 through Cycle 6 Day 28; assessed at baseline and every 8 weeks thereafter
Time frame: Approximately 1 year (since initiation of Phase II, Dec 2013, till Primary CSR cut off 06Jan2015)
Cmax of BYL - Phase Ib
Serum concentration for BYL719 (alpelisib) 1 cycle - 28 days of treatment
Time frame: Cycle 1 Day 1, Cycle 1 Day 15
Area Under Curve (AUC) 0-24 Hour of BYL - Phase Ib
Area under curve for BYL719 (alpelisib) 1 cycle - 28 days of treatment
Time frame: Cycle 1 Day 1 (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose), Cycle 1 Day 15 (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose)
Tmax and T Half of BYL - Phase Ib
Tmax and half life of BYL719 (Alpelisib) 1 cycle - 28 days of treatment
Time frame: Cycle 1 Day 1, Cycle 1 Day 15
Cmax of AMG - Phase Ib
Serum concentration for AMG 479 (ganitumab) 1 cycle - 28 days of treatment
Time frame: Cycle 1 Day 15
Area Under Curve (AUC) 0-336 Hour of AMG - Phase Ib
Area under curve for AMG 479 (ganitumab) 1 cycle - 28 days of treatment
Time frame: Cycle 1 Day 15 (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose)
Tmax and T Half of AMG - Phase Ib
Tmax and half life of AMG 479 (ganitumab) 1 cycle - 28 days of treatment
Time frame: Cycle 1 Day 15
| Milestone | BYL 200mg + AMG 12mg/kg | BYL 300mg + AMG 12mg/kg | BYL 350mg + AMG 12mg/kg | HR+BC - Phase II | Ovarian - Phase II | Non-HR+BC/Ovarian - Phase II |
|---|---|---|---|---|---|---|
| Started | 4 | 10 | 10 | 16 | 6 | 1 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 10 | 10 | 16 | 6 | 1 |
| Withdrew: Adverse event | 1 | 3 | 4 | 2 | 3 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Administrative problems | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 3 | 5 | 5 | 13 | 3 | 0 |
Phase lb only
| Participants | BYL 200mg + AMG 12mg/kg | BYL 300mg + AMG 12mg/kg | BYL 350mg + AMG 12mg/kg |
|---|---|---|---|
| Drug hypersensitivity | 0 | 0 | 1 |
| Hyperglycemia | 0 | 0 | 1 |
| Rash maculopapular | 0 | 1 | 0 |
| Urticaria | 0 | 1 | 0 |
The antitumor activity of alpelisib in combination with ganitumab in patients with PIK3CA mutated or amplified hormone receptor positive (HR+) breast (arm 1) or ovarian (arm 2) cancer. Overall response rate is defined as the proportion of patients who have a best overall response of complete response or partial response assessed per RECIST 1.1.
| Percentages of participants | HR+BC - Phase II | Ovarian - Phase II | All Patients - Phase |
|---|---|---|---|
| Percentage of Patients With Overall Response Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II | 12.5 (1.6 to 38.3) | 16.7 (0.4 to 64.1) | 13.0 (2.8 to 33.6) |
The anti-tumor activity of alpelisib and ganitumab in combination as per RECIST 1.1
| Participants | BYL 200mg + AMG 12mg/kg | BYL 300mg + AMG 12mg/kg | BYL 350mg + AMG 12mg/kg |
|---|---|---|---|
| Complete response (CR) | 0 | 0 | 0 |
| Partial response (PR) | 0 | 0 | 3 |
| Stable disease (PD) | 1 | 3 | 2 |
| Progressive disease (PD) | 3 | 3 | 3 |
| Unknown | 0 | 4 | 2 |
The anti-tumor activity of alpelisib and ganitumab in combination as per RECIST 1.1
| Percentages of participants | BYL 200mg + AMG 12mg/kg | BYL 300mg + AMG 12mg/kg | BYL 350mg + AMG 12mg/kg |
|---|---|---|---|
| Percentage of Patients With Disease Control Rate (RECIST) Based on Investigator Radiology Assessment - Phase Ib | 25.0 (0.6 to 80.6) | 9.1 (6.7 to 65.2) | 50.0 (18.7 to 81.3) |
the antitumor activity of alpelisib in combination with ganitumab in patients with PIK3CA mutated or amplified hormone receptor positive (HR+) breast (arm 1) or ovarian (arm 2) cancer. Phase II only, Cycle 1 Day 1 through Cycle 6 Day 28; assessed at baseline and every 8 weeks thereafter
| Percentages of participants | HR+BC - Phase II | Ovarian - Phase II | All Patients - Phase II |
|---|---|---|---|
| Percentage of Patients With Disease Control Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II | 43.8 (19.8 to 70.1) | 50.0 (11.8 to 88.2) | 47.8 (26.8 to 69.4) |
Serum concentration for BYL719 (alpelisib) 1 cycle - 28 days of treatment
| ng/mL | BYL 200mg + AMG 12mg/kg | BYL 300mg + AMG 12mg/kg | BYL 350mg + AMG 12mg/kg |
|---|---|---|---|
| Cycle 1 Day 1 | 2070 ± 1040 | 2620 ± 1260 | 2640 ± 888 |
| Cycle 1 day 15 | 3080 ± 1750 | 2880 ± 910 | 2600 ± 1040 |
Area under curve for BYL719 (alpelisib) 1 cycle - 28 days of treatment
| hr*ng/mL | BYL 200mg + AMG 12mg/kg | BYL 300mg + AMG 12mg/kg | BYL 350mg + AMG 12mg/kg |
|---|---|---|---|
| Cycle 1 Day 1 | 19900 ± 8700 | 23400 ± 10500 | 25200 ± 9200 |
| Cycle 1 day 15 | 24000 ± 10700 | 29700 ± 9170 | 25200 ± 9160 |
Tmax and half life of BYL719 (Alpelisib) 1 cycle - 28 days of treatment
| hr | BYL 200mg + AMG 12mg/kg | BYL 300mg + AMG 12mg/kg | BYL 350mg + AMG 12mg/kg |
|---|---|---|---|
| Tmax (Cycle 1 Day 1) | 2.78 (1.88 to 3.55) | 1.97 (0.63 to 3.00) | 2.36 (1.50 to 3.10) |
| Tmax (Cycle 1 Day 15) | 1.57 (0.83 to 1.83) | 3.01 (2.07 to 4.00) | 2.02 (2.00 to 3.08) |
| Thalf (Cycle 1 Day 1) | 7.78 (6.24 to 10.80) | 6.06 (5.26 to 13.70) | 6.86 (5.32 to 9.23) |
| Thalf (Cycle 1 Day15) | 6.89 (5.94 to 9.90) | 6.80 (5.82 to 8.81) | 6.83 (5.19 to 13.00) |
Serum concentration for AMG 479 (ganitumab) 1 cycle - 28 days of treatment
| ng/mL | BYL 200mg + AMG 12mg/kg | BYL 300mg + AMG 12mg/kg | BYL 350mg + AMG 12mg/kg |
|---|---|---|---|
| Cmax of AMG - Phase Ib | 192 ± 24 | 202 ± 43.3 | 232 ± 59.3 |
Area under curve for AMG 479 (ganitumab) 1 cycle - 28 days of treatment
| hr*ng/mL | BYL 200mg + AMG 12mg/kg | BYL 300mg + AMG 12mg/kg | BYL 350mg + AMG 12mg/kg |
|---|---|---|---|
| Area Under Curve (AUC) 0-336 Hour of AMG - Phase Ib | 22900 ± 3930 | 22500 ± 7040 | 25200 ± 8000 |
Tmax and half life of AMG 479 (ganitumab) 1 cycle - 28 days of treatment
| hr | BYL 200mg + AMG 12mg/kg | BYL 300mg + AMG 12mg/kg | BYL 350mg + AMG 12mg/kg |
|---|---|---|---|
| Tmax | 21.20 (1.02 to 22.70) | 1.02 (1.00 to 23.10) | 1.07 (1.00 to 1.77) |
| Thalf | 132 (117 to 148) | 117 (109 to 161) | 180 (98 to 283) |
Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BYL 200mg + AMG 12 mg/kg | 4/4 (100%) | 1/4 (25%) | 4/4 (100%) |
| BYL 300mg + AMG 12 mg/kg | 8/10 (80%) | 5/10 (50%) | 10/10 (100%) |
| BYL 350mg + AMG 12 mg/kg | 8/10 (80%) | 5/10 (50%) | 10/10 (100%) |
| HR + BC - Phase II | 13/16 (81.3%) | 9/16 (56.3%) | 16/16 (100%) |
| Ovarian - Phase II | 5/6 (83.3%) | 5/6 (83.3%) | 6/6 (100%) |
| Event | BYL 200mg + AMG 12 mg/kg | BYL 300mg + AMG 12 mg/kg | BYL 350mg + AMG 12 mg/kg | HR + BC - Phase II | Ovarian - Phase II |
|---|---|---|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 0/4 | 0/10 | 1/10 | 2/16 | 3/6 |
| Drug hypersensitivityImmune system disorders | 1/4 | 0/10 | 0/10 | 0/16 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/4 | 1/10 | 0/10 | 0/16 | 1/6 |
| AstheniaGeneral disorders | 0/4 | 0/10 | 0/10 | 1/16 | 1/6 |
| PyrexiaGeneral disorders | 0/4 | 0/10 | 0/10 | 0/16 | 1/6 |
| Blood creatinine increasedInvestigations | 0/4 | 0/10 | 0/10 | 0/16 | 1/6 |
| DehydrationMetabolism and nutrition disorders | 0/4 | 0/10 | 0/10 | 0/16 | 1/6 |
| MyositisMusculoskeletal and connective tissue disorders | 0/4 | 0/10 | 0/10 | 0/16 | 1/6 |
| Large intestinal obstructionGastrointestinal disorders | 0/4 | 1/10 | 0/10 | 0/16 | 0/6 |
| Bile duct stenosisHepatobiliary disorders | 0/4 | 0/10 | 1/10 | 0/16 | 0/6 |
| Event | BYL 200mg + AMG 12 mg/kg | BYL 300mg + AMG 12 mg/kg | BYL 350mg + AMG 12 mg/kg | HR + BC - Phase II | Ovarian - Phase II |
|---|---|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 1/4 | 5/10 | 6/10 | 8/16 | 6/6 |
| NauseaGastrointestinal disorders | 0/4 | 9/10 | 5/10 | 7/16 | 3/6 |
| Weight decreasedInvestigations | 2/4 | 5/10 | 9/10 | 6/16 | 2/6 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/4 | 7/10 | 9/10 | 9/16 | 4/6 |
| FatigueGeneral disorders | 2/4 | 6/10 | 8/10 | 7/16 | 2/6 |
| StomatitisGastrointestinal disorders | 3/4 | 3/10 | 5/10 | 6/16 | 3/6 |
| Blood creatinine increasedInvestigations | 3/4 | 3/10 | 2/10 | 0/16 | 2/6 |
| HeadacheNervous system disorders | 3/4 | 1/10 | 2/10 | 5/16 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 2/4 | 5/10 | 7/10 | 10/16 | 3/6 |
| VomitingGastrointestinal disorders | 0/4 | 6/10 | 4/10 | 4/16 | 3/6 |
Full analysis set
| Age, Continuous(years) | BYL 200mg + AMG 12mg/kg | BYL 300mg + AMG 12mg/kg | BYL 350mg + AMG 12mg/kg | HR+BC - Phase II | Ovarian - Phase II | Non-HR+BC/Ovarian - Phase II | Total |
|---|---|---|---|---|---|---|---|
| Mean | 50.5 ± 3.11 | 57.5 ± 15.55 | 63.7 ± 7.83 | 51.3 ± 8.04 | 59.7 ± 6.53 | 56.0 ± 0 | 56.3 ± 10.54 |
| Sex: Female, Male(Participants) | BYL 200mg + AMG 12mg/kg | BYL 300mg + AMG 12mg/kg | BYL 350mg + AMG 12mg/kg | HR+BC - Phase II | Ovarian - Phase II | Non-HR+BC/Ovarian - Phase II | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 7 | 7 | 15 | 6 | 1 | 40 |
| Male | 0 | 3 | 3 | 1 | 0 | 0 | 7 |
| Race/Ethnicity, Customized(Participants) | BYL 200mg + AMG 12mg/kg | BYL 300mg + AMG 12mg/kg | BYL 350mg + AMG 12mg/kg | HR+BC - Phase II | Ovarian - Phase II | Non-HR+BC/Ovarian - Phase II | Total |
|---|---|---|---|---|---|---|---|
| Caucasian | 2 | 8 | 10 | 14 | 5 | 1 | 40 |
| Asian | 2 | 2 | 0 | 2 | 0 | 0 | 6 |
| Native American | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Nov 2012 to primary completion in Dec 2014, 24 months.
Results were first posted in Jun 2018, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alpelisib · Ganitumab